Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Choose the Right Internet based Degree Program for Your Future - 2Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- 3Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- 47 Methods for further developing Rest Quality
- 5Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
- Porsche May Kill the Electric Boxster Before It Ever Arrives
- These are the Fastest Italian Sports Cars
- Journey Travel Objections for Your Next Experience
- Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- The race is on to turn your body into a GLP-1 factory
- Beating Wellbeing Difficulties: Individual Victories in Health
- Real time features for Films and Programs
- Top 10 Moving Style Architects of the Year
- Pick Your Favored method of transportation
